Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis.
The cysteine proteinase cathepsin B has been implicated in tumor progression by virtue of its increased mRNA and protein levels, as well as its localization at the invading front of the tumor. In this study, we examined whether blocking cathepsin B expression in human glioblastoma SNB19 cells affects angiogenesis. Stable transfectants of human glioblastoma cells with a plasmid containing antisense cathepsin B cDNA showed decreased migration rates in wound- and spheroid-migration assays. Analysis showed a reduction in VEGF protein and MMP-9 activity in the cathepsin B antisense cDNA-transfected cells. Regarding angiogenesis in vitro, we found that the conditioned medium of glioblastoma cells with downregulated cathepsin B expression reduced cell-cell interaction of human microvascular endothelial cells, resulting in the disruption of capillary-like network formation. Furthermore, a marked reduction in microvasculature development was seen in an in vivo dorsal air sac assay of glioblastoma cells with downregulated cathepsin B expression. Taken together, these results provide evidence that inhibition of cathepsin B expression can suppress glioblastoma-induced neovascularization.
Yanamandra
Niranjan
N
Program of Cancer Biology, University of Illinois College of Medicine at Peoria, Peoria, One Illini Drive, Box 1649, IL 61656, USA.
Gumidyala
Krishna V
KV
Waldron
Kevin G
KG
Gujrati
Meena
M
Olivero
William C
WC
Dinh
Dzung H
DH
Rao
Jasti S
JS
Mohanam
Sanjeeva
S
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D001681:Biological Assay; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002401:Cathepsin B / Q000037:antagonists & inhibitors*; D045744:Cell Line, Tumor; D002465:Cell Movement; D002867:Chromones / Q000494:pharmacology; D017077:Culture Media, Conditioned; D016895:Culture Media, Serum-Free; D004730:Endothelium, Vascular / Q000166:cytology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005419:Flavonoids / Q000494:pharmacology; D005909:Glioblastoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D061965:Matrix Metalloproteinase Inhibitors; D051379:Mice; D008819:Mice, Nude; D009025:Morpholines / Q000494:pharmacology; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014162:Transfection; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D002867:Chromones; D017077:Culture Media, Conditioned; D016895:Culture Media, Serum-Free; D004791:Enzyme Inhibitors; D005419:Flavonoids; D061965:Matrix Metalloproteinase Inhibitors; D009025:Morpholines; D042461:Vascular Endothelial Growth Factor A; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; D002401:Cathepsin B; D013755:Tetradecanoylphorbol Acetate; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one